Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$6.49 +1.9%	$6.19	$3.93 ▼ $7.32	$325.87M	1.54	652,285 shs	769,569 shs
CABA Cabaletta Bio	$1.44 -5.3%	$1.77	$0.99 ▼ $6.74	$77.13M	2.74	1.15 million shs	935,451 shs
CADL Candel Therapeutics	$6.29 -2.5%	$5.74	$3.79 ▼ $14.60	$322.91M	-0.91	978,671 shs	592,013 shs
GLUE Monte Rosa Therapeutics	$4.79 -3.2%	$4.95	$3.50 ▼ $12.40	$304.47M	1.42	439,912 shs	578,534 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	+1.88%	-0.61%	+10.56%	-1.07%	+32.45%
CABA Cabaletta Bio	-5.26%	-13.25%	-10.00%	+7.46%	-79.72%
CADL Candel Therapeutics	-2.48%	-10.40%	+26.05%	+19.13%	+6.07%
GLUE Monte Rosa Therapeutics	-3.23%	-15.52%	+1.27%	-3.62%	+5.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABEO Abeona Therapeutics	3.5155 of 5 stars	3.5	1.0	4.5	1.1	2.5	0.0
CABA Cabaletta Bio	1.7785 of 5 stars	3.5	2.0	0.0	1.1	0.8	0.6
CADL Candel Therapeutics	2.1795 of 5 stars	3.6	2.0	0.0	1.4	1.7	0.6
GLUE Monte Rosa Therapeutics	1.2465 of 5 stars	3.3	0.0	0.0	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	3.00	Buy	$19.25	196.61% Upside
CABA Cabaletta Bio	3.00	Buy	$14.43	901.98% Upside
CADL Candel Therapeutics	3.20	Buy	$22.00	249.76% Upside
GLUE Monte Rosa Therapeutics	2.67	Moderate Buy	$15.33	220.11% Upside

Current Analyst Ratings Breakdown

Latest CABA, CADL, GLUE, and ABEO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/9/2025	CADL Candel Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/30/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$23.00
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/2/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$19.00
5/16/2025	ABEO Abeona Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $20.00
5/16/2025	CABA Cabaletta Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $13.00
5/15/2025	ABEO Abeona Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/15/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$3.50M	94.87	N/A	N/A	$1.01 per share	6.43
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$3.12 per share	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$1.41 per share	N/A
GLUE Monte Rosa Therapeutics	$75.62M	3.90	N/A	N/A	$3.63 per share	1.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	-$63.73M	-$1.27	N/A	N/A	N/A	N/A	-118.82%	-52.48%	8/11/2025 (Estimated)
CABA Cabaletta Bio	-$115.86M	-$2.54	N/A	N/A	N/A	N/A	-78.29%	-65.68%	8/6/2025 (Estimated)
CADL Candel Therapeutics	-$55.18M	-$1.34	N/A	N/A	N/A	N/A	-136.74%	-63.13%	8/12/2025 (Estimated)
GLUE Monte Rosa Therapeutics	-$72.70M	$0.08	59.88	N/A	N/A	3.86%	2.65%	1.65%	8/14/2025 (Estimated)

Latest CABA, CADL, GLUE, and ABEO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CABA Cabaletta Bio	-$0.71	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	GLUE Monte Rosa Therapeutics	-$0.31	N/A	N/A	N/A	$7.23 million	N/A
8/12/2025	Q2 2025	CADL Candel Therapeutics	-$0.17	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ABEO Abeona Therapeutics	-$0.39	N/A	N/A	N/A	$21.71 million	N/A
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A
5/15/2025	Q1 2025	ABEO Abeona Therapeutics	-$0.35	-$0.24	+$0.11	-$0.24	N/A	N/A
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A
5/8/2025	Q1 2025	GLUE Monte Rosa Therapeutics	-$0.24	$0.57	+$0.81	$0.57	$13.57 million	$84.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.27	4.90	4.90
CABA Cabaletta Bio	N/A	3.96	3.96
CADL Candel Therapeutics	0.01	4.64	4.64
GLUE Monte Rosa Therapeutics	N/A	5.61	5.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
CABA Cabaletta Bio	N/A
CADL Candel Therapeutics	13.93%
GLUE Monte Rosa Therapeutics	79.96%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	6.90%
CABA Cabaletta Bio	11.25%
CADL Candel Therapeutics	16.60%
GLUE Monte Rosa Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	51.16 million	47.63 million	Optionable
CABA Cabaletta Bio	50	50.74 million	45.03 million	Optionable
CADL Candel Therapeutics	60	50.10 million	41.79 million	Optionable
GLUE Monte Rosa Therapeutics	90	61.51 million	57.27 million	Optionable

CABA, CADL, GLUE, and ABEO Headlines

Recent News About These Companies

Readystate Asset Management LP Acquires Shares of 287,000 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

July 23, 2025 | marketbeat.com

Monte Rosa doses first subjects in trial of MRT-8102 for inflammatory conditions

July 22, 2025 | msn.com

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

July 21, 2025 | globenewswire.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 7.3% - Should You Buy?

July 17, 2025 | marketbeat.com

Molecular glue degraders are more versatile than previously thought

July 3, 2025 | cen.acs.orgC

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

July 3, 2025 | globenewswire.com

Monte Rosa’s molecular glue degrader MRT-8102 gains IND clearance for inflammatory conditions

June 12, 2025 | bioworld.comB

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

June 10, 2025 | globenewswire.com

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet

June 9, 2025 | zacks.com

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Roche strikes Orionis deal to develop ‘molecular glues’ for cancer

May 21, 2025 | biopharmadive.comB

Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates

May 8, 2025 | zacks.com

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

May 8, 2025 | globenewswire.com

Why Monte Rosa Therapeutics, Inc.’s (GLUE) Stock Is Down 6.04%

May 6, 2025 | aaii.comA

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

April 28, 2025 | globenewswire.com

Monte Rosa Therapeutics Insider Ups Holding During Year

April 22, 2025 | finance.yahoo.com

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Director Acquires $58,400.00 in Stock

March 26, 2025 | insidertrades.com

Monte Rosa Therapeutics: Exercise Extreme Caution

March 25, 2025 | seekingalpha.com

Monte Rosa Therapeutics price target raised to $17 from $15 at Wedbush

March 23, 2025 | markets.businessinsider.com

Monte Rosa Therapeutics price target lowered to $10 from $11 at Wells Fargo

March 22, 2025 | markets.businessinsider.com

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call Transcript

March 22, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA, CADL, GLUE, and ABEO Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$6.49 +0.12 (+1.88%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$6.52 +0.03 (+0.52%)

As of 08/1/2025 07:57 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Cabaletta Bio NASDAQ:CABA

$1.44 -0.08 (-5.26%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.48 +0.05 (+3.13%)

As of 08/1/2025 07:59 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Candel Therapeutics NASDAQ:CADL

$6.29 -0.16 (-2.48%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$6.28 0.00 (-0.08%)

As of 08/1/2025 06:28 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Monte Rosa Therapeutics NASDAQ:GLUE

$4.79 -0.16 (-3.23%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$4.79 0.00 (0.00%)

As of 08/1/2025 04:10 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time